EN PL
ORIGINAL PAPER
Comparison of clinical and serological parameters in female and male patients with systemic sclerosis
 
More details
Hide details
 
Submission date: 2015-10-22
 
 
Final revision date: 2015-12-09
 
 
Acceptance date: 2016-01-08
 
 
Online publication date: 2016-02-11
 
 
Publication date: 2016-02-15
 
 
Reumatologia 2015;53(6):315-320
 
KEYWORDS
TOPICS
ABSTRACT
Objectives: The course of systemic sclerosis (SSc) can differ in female and male patients. According to the literature the incidence rates of diffuse cutaneous SSc, scleroderma renal crisis and digital ulceration are higher in male patients. The aim of the study was to compare selected clinical and serological parameters in male and female patients with SSc.
Material and methods: The study encompassed 101 European Caucasian patients with SSc, including 23 men, hospitalized in the Department of Rheumatology. Patients fulfilled the American Rheumatism Association (ARA) classification criteria for SSc. The study groups of men and women were assessed according to the SSc subtype, incidence of internal organ involvement and presence of antinuclear antibodies considered SSc markers.
Results: Diffuse cutaneous (dc) SSc was observed more commonly in men than in women (13/23 vs. 25/78; p = 0.03). The time from the development of Raynaud’s phenomenon to the diagnosis was significantly shorter in male compared to female patients (3.2 ±4.7 vs. 7.5 ±7.1; p = 0.01). The incidence of scleroderma renal crisis (SRC) was significantly higher (3/23 vs. 2/78; p = 0.04) and of other calcifications significantly lower in the male group compared to the female group (1/23 vs. 20/78; p = 0.02).
Conclusions: We concluded that the incidence of dcSSc is higher in men compared to women. The time from the development of Raynaud’s phenomenon to the diagnosis is shorter in the male compare to female group. The incidence of SRC is higher, whereas that of calcifications is lower in SSc men. The serological profiles of female and male patients with SSc are comparable.
 
REFERENCES (29)
1.
BellandoRandone S, Guiducci S, MatucciCerinic M. Very early diagnosis of systemic sclerosis. Pol Arch Med Wewn 2012; 122: 18-23.
 
2.
Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-277.
 
3.
Hudson M, Thombs B, Baron M. Canadian Scleroderma Research Group: Time to diagnosis in systemic sclerosis: is sex a factor? Arthritis Rheum 2009; 61: 274-278.
 
4.
Mendoza F, Derk CT. Systemic sclerosis mortality in the United States: 1999-2002 implications for patient care. J Clin Rheumatol 2007; 13: 187-192.
 
5.
Lambova S. Cardiac manifestations in systemic sclerosis. World J Cardiol 2014; 26: 993-1005.
 
6.
Sierakowska M, Sierakowski S, Doroszkiewicz H, et al. Symptoms from the internal organs of patients with systemic sclerosis in the light of selected diagnostic tests. Pol Merkur Lekarski 2011; 30: 116-120.
 
7.
Widuchowska M, Głowacka M, Kopeć-Mędrek M, et al. Postępująca twardzina układowa o niepomyślnym przebiegu u mężczyzn. Reumatologia 2010; 48: 45-48.
 
8.
Hasegawa M, Hatta Y, Matsushita T, et al. Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Mod Rheumatol 2013; 23: 913-919.
 
9.
Chan PT, Mok CC, Chan KL, et al. Functioning and health-related quality of life in Chinese patients with systemic sclerosis: a case-control study. Clin Rheumatol 2014; 33: 659-666.
 
10.
Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3USethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30: 332-346.
 
11.
Ohta A, Nagai M, Nishina M, et al. Age at onset and gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol 2013; 23: 759-764.
 
12.
Panopoulos ST, Bournia VK, Sfikakis PP. Is vasculopathy associated with systemic sclerosis more severe in men? J Rheumatol 2013; 40: 46-51.
 
13.
Mihai C, Landewé R, van der Heijde D, et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 2015. doi: 10.1136/annrheumdis-2014-205897.
 
14.
Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014; 146: 1494-1504.
 
15.
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
 
16.
LeRoy EC, Black C, Fleishmajer R. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-204.
 
17.
Ariani A, Silva M, Bravi E, et al. Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: A multi-centric study. Mod Rheumatol 2015; 30: 1-7.
 
18.
Patiwetwitoon S, Wangkaew S, Euathrongchit J, et al. High-resolution computed tomographic findings in systemic sclerosis-associated interstitial lung disease: comparison between diffuse and limited systemic sclerosis. J Clin Rheumatol 2012; 18: 229-233.
 
19.
Guarnieri G, Zanatta E, Mason P, et al. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis. Clin Exp Rheumatol 2015; 33 (4 Suppl 91): S80-S86.
 
20.
Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015; 41: 237-248.
 
21.
Foocharoen C, Mahakkanukrauh A, Pussadhamma B, et al. Incidence of pulmonary hypertension in patients with systemic sclerosis and no pulmonary symptoms: is annual echocardiographic screening necessary? J Clin Rheumatol 2014; 20: 268-274.
 
22.
Wielosz E, Dryglewska M, Majdan M. Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. Clin Rheumatol 2009; 28: 955-259.
 
23.
Nashid M, Khanna PP, Furst DE, et al. Gender and ethnicity differences in patients with diffuse systemic sclerosis – analysis from three large randomized clinical trials. Rheumatology (Oxford) 2011; 50: 335-342.
 
24.
Gaultier JB, Hot A, Cathébras P, et al. Systemic sclerosis in men. Rev Med Interne 2008; 29: 181-186.
 
25.
Delisle VC, Hudson M, Baron M, et al. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry. Clin Exp Rheumatol 2014; 32: 10-14.
 
26.
Elhai M, Avouac J, Walker UA, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2016; 75: 163-169.
 
27.
Jung M, Bonner A, Hudson M, et al. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. Scand Rheum 2014; 43: 217-220.
 
28.
Frech T, Walker AE, Barrett-O’Keefe Z, et al. Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clin Rheumatol 2015; 34: 905-913.
 
29.
Strickland G, Pauling J, Cavill C, et al. Mortality in systemic sclerosis – a single centre study from the UK. Clin Rheumatol 2013; 32: 1533-1539.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top